{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T21:10:59Z","timestamp":1760562659751,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010096","name":"Southern Medical University","doi-asserted-by":"publisher","award":["2025D04J0037"],"award-info":[{"award-number":["2025D04J0037"]}],"id":[{"id":"10.13039\/501100010096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.109011","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:51:44Z","timestamp":1758613904000},"page":"109011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identification of novel selective estrogen receptor degraders (SERD) via physics-based and deep-learning-based virtual screening and Bioassys"],"prefix":"10.1016","volume":"165","author":[{"given":"Mengyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengye","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoya","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanxin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2025.109011_bb0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109011_bb0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109011_bb0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acs.jmedchem.9b01293","volume":"63","author":"El-Ahmad","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109011_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102432","article-title":"Accelerating drug development in breast cancer: new frontiers for ER inhibition","volume":"109","author":"Ferraro","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"13","key":"10.1016\/j.bioorg.2025.109011_bb0025","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1021\/acs.jmedchem.3c00136","article-title":"Targeting the estrogen receptor for the treatment of breast Cancer: recent advances and challenges","volume":"66","author":"Rej","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109011_bb0030","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1042\/EBC20200174","article-title":"Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer","volume":"65","author":"Haines","year":"2021","journal-title":"Essays Biochem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109011_bb0035","first-page":"253","article-title":"Tamoxifen, raloxifene, and the prevention of breast cancer","volume":"20","author":"Jordan","year":"1999","journal-title":"Endocr. Rev."},{"issue":"14","key":"10.1016\/j.bioorg.2025.109011_bb0040","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1016\/j.bmcl.2013.05.067","article-title":"Structure-activity relationships of bisphenol a analogs at estrogen receptors (ERs): discovery of an ERalpha-selective antagonist","volume":"23","author":"Maruyama","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109011_bb0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ardp.200800174","article-title":"Breast cancer, estrogen receptor and ligands","volume":"342","author":"Bai","year":"2009","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bioorg.2025.109011_bb0050","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6605599","article-title":"Epidemiology and pathophysiology of cancer-associated thrombosis","volume":"102 Suppl 1(Suppl 1)","author":"Noble","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109011_bb0055","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.21037\/tcr-19-1956","article-title":"Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review","volume":"9","author":"Oceguera-Basurto","year":"2020","journal-title":"Transl. Cancer Res."},{"issue":"10001","key":"10.1016\/j.bioorg.2025.109011_bb0060","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Patient-level meta-analysis of the randomised trials","volume":"386","author":"Aromatase inhibitors versus tamoxifen in early breast cancer","year":"2015","journal-title":"Lancet"},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2025.109011_bb0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2011.02.001","article-title":"Aromatase, aromatase inhibitors, and breast cancer","volume":"125","author":"Chumsri","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"47","key":"10.1016\/j.bioorg.2025.109011_bb0070","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1038\/sj.onc.1206937","article-title":"Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling","volume":"22","author":"Clarke","year":"2003","journal-title":"Oncogene"},{"issue":"8941","key":"10.1016\/j.bioorg.2025.109011_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(95)91156-1","article-title":"Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer","volume":"345","author":"Howell","year":"1995","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.bioorg.2025.109011_bb0080","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1158\/1078-0432.CCR-20-0224","article-title":"ESR1 mutations and overall survival on Fulvestrant versus Exemestane in advanced hormone receptor-positive breast Cancer: a combined analysis of the phase III SoFEA and EFECT trials","volume":"26","author":"Turner","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109011_bb0085","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0014-5793(99)00343-9","article-title":"Implication of proteasome in estrogen receptor degradation","volume":"448","author":"El","year":"1999","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109011_bb0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0969-2126(01)00568-8","article-title":"Structural insights into the mode of action of a pure antiestrogen","volume":"9","author":"Pike","year":"2001","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109011_bb0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40487-017-0046-2","article-title":"A review of Fulvestrant in breast Cancer","volume":"5","author":"Nathan","year":"2017","journal-title":"Oncol Ther"},{"key":"10.1016\/j.bioorg.2025.109011_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113869","article-title":"Human estrogen receptor alpha antagonists, part 2: synthesis driven by rational design, in vitro antiproliferative, and in vivo anticancer evaluation of innovative coumarin-related antiestrogens as breast cancer suppressants","volume":"227","author":"Kurtanovic","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109011_bb0105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10549-024-07595-1","article-title":"Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences","volume":"209","author":"Scafetta","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"issue":"28","key":"10.1016\/j.bioorg.2025.109011_bb0110","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast Cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109011_bb0115","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2174\/1381612822666151125000550","article-title":"Computer aided drug design: success and limitations","volume":"22","author":"Baig","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"15","key":"10.1016\/j.bioorg.2025.109011_bb0120","doi-asserted-by":"crossref","first-page":"10691","DOI":"10.1021\/acs.jmedchem.2c00991","article-title":"Boosting protein-ligand binding pose prediction and virtual screening based on residue-atom distance likelihood potential and graph transformer","volume":"65","author":"Shen","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109011_bb0125","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2289355","article-title":"Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and in vitro and in vivo biological activity evaluations","volume":"39","author":"Jin","year":"2024","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109011_bb0130","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41596-021-00659-2","article-title":"Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking","volume":"17","author":"Gentile","year":"2022","journal-title":"Nat. Protoc."},{"issue":"9","key":"10.1016\/j.bioorg.2025.109011_bb0135","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s43588-023-00511-5","article-title":"Efficient and accurate large library ligand docking with KarmaDock","volume":"3","author":"Zhang","year":"2023","journal-title":"Nat Comput Sci"},{"issue":"20","key":"10.1016\/j.bioorg.2025.109011_bb0140","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1021\/jm060999m","article-title":"Prediction of protein-ligand interactions. Docking and scoring: successes and gaps","volume":"49","author":"Leach","year":"2006","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2025.109011_bb0145","doi-asserted-by":"crossref","first-page":"14530","DOI":"10.1021\/acs.jmedchem.0c01163","article-title":"Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist","volume":"63","author":"Scott","year":"2020","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2025.109011_bb0150","doi-asserted-by":"crossref","first-page":"11841","DOI":"10.1021\/acs.jmedchem.1c00847","article-title":"GDC-9545 (Giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast Cancer","volume":"64","author":"Liang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109011_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116897","article-title":"Discovery of non-antiproliferative selective estrogen receptor degraders (SERDs) based on scaffold optimization of elacestrant","volume":"279","author":"Lu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109011_bb0160","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1021\/acs.jmedchem.2c00008","article-title":"Discovery of Thieno[2,3-e] indazole derivatives as novel Oral selective estrogen receptor degraders with highly improved antitumor effect and favorable Druggability","volume":"65","author":"Lu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109011_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116534","article-title":"Discovery of novel quinoline scaffold selective estrogen receptor degraders (SERDs) for treatment of ER positive breast cancer with enhanced antiproliferative bioactivity through immunogenic cell death (ICD) effects","volume":"275","author":"Lu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109011_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115324","article-title":"Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer","volume":"253","author":"Lu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2025.109011_bb0175","doi-asserted-by":"crossref","first-page":"15094","DOI":"10.1021\/acs.jmedchem.0c00913","article-title":"Selective estrogen receptor degraders (SERDs): a promising strategy for estrogen receptor positive endocrine-resistant breast Cancer","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109011_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176424","article-title":"Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer","volume":"969","author":"Guglielmi","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109011_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102825","article-title":"Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review","volume":"130","author":"Gheysen","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109011_bb0190","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/s41467-018-04413-3","article-title":"Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity","volume":"9","author":"Fanning","year":"2018","journal-title":"Nat. Commun."},{"issue":"D1","key":"10.1016\/j.bioorg.2025.109011_bb0195","doi-asserted-by":"crossref","first-page":"D1045","DOI":"10.1093\/nar\/gkv1072","article-title":"BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology","volume":"44","author":"Gilson","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"14","key":"10.1016\/j.bioorg.2025.109011_bb0200","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1021\/jm300687e","article-title":"Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking","volume":"55","author":"Mysinger","year":"2012","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109011_bb0205","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: improving force field accuracy on challenging regimes of chemical space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theory Comput."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109011_bb0210","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"issue":"1\u20133","key":"10.1016\/j.bioorg.2025.109011_bb0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"21","key":"10.1016\/j.bioorg.2025.109011_bb0220","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:33:25Z","timestamp":1760560405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825008910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":44,"alternative-id":["S0045206825008910"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109011","relation":{},"ISSN":["0045-2068"],"issn-type":[{"type":"print","value":"0045-2068"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of novel selective estrogen receptor degraders (SERD) via physics-based and deep-learning-based virtual screening and Bioassys","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109011"}}